XenoPort Company Description
Some athletes take drugs for better performance, but what can a drug take to improve its performance? A new route! XenoPort is working to improve drugs' bioavailability, or their ability to be absorbed by tissues in the body. The development-stage firm is using genomics to identify transporter proteins. It then designs oral drug molecules to find and ride these transporters through the gastrointestinal tract to their destination. Xenoport has four drug candidates in clinical trials with more in preclinical development. All are based on existing drugs with the aim of improving their effectiveness, reducing side effects, and requiring less frequent dosings.
View the Comprehensive Company Description for XenoPort
The Company Description provides a historical perspective of XenoPort's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of XenoPort's evolution in the marketplace.
